JPWO2021169845A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021169845A5
JPWO2021169845A5 JP2022550720A JP2022550720A JPWO2021169845A5 JP WO2021169845 A5 JPWO2021169845 A5 JP WO2021169845A5 JP 2022550720 A JP2022550720 A JP 2022550720A JP 2022550720 A JP2022550720 A JP 2022550720A JP WO2021169845 A5 JPWO2021169845 A5 JP WO2021169845A5
Authority
JP
Japan
Prior art keywords
treatment
patient
nrg
neuregulin
probnp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022550720A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023514738A (ja
JP2023514738A5 (https=
JP7807815B2 (ja
Publication date
Priority claimed from CN202010174086.5A external-priority patent/CN113289002A/zh
Application filed filed Critical
Publication of JP2023514738A publication Critical patent/JP2023514738A/ja
Publication of JP2023514738A5 publication Critical patent/JP2023514738A5/ja
Publication of JPWO2021169845A5 publication Critical patent/JPWO2021169845A5/ja
Priority to JP2025205790A priority Critical patent/JP2026062640A/ja
Application granted granted Critical
Publication of JP7807815B2 publication Critical patent/JP7807815B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022550720A 2020-02-24 2021-02-19 ニューレグリンの使用による心不全を予防、治療、又は遅延させるための方法及び組成物 Active JP7807815B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025205790A JP2026062640A (ja) 2020-02-24 2025-11-27 ニューレグリンの使用による心不全を予防、治療、又は遅延させるための方法及び組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010113391.3 2020-02-24
CN202010113391 2020-02-24
CN202010174086.5 2020-03-13
CN202010174086.5A CN113289002A (zh) 2020-02-24 2020-03-13 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物
PCT/CN2021/076772 WO2021169845A1 (zh) 2020-02-24 2021-02-19 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025205790A Division JP2026062640A (ja) 2020-02-24 2025-11-27 ニューレグリンの使用による心不全を予防、治療、又は遅延させるための方法及び組成物

Publications (4)

Publication Number Publication Date
JP2023514738A JP2023514738A (ja) 2023-04-07
JP2023514738A5 JP2023514738A5 (https=) 2024-02-29
JPWO2021169845A5 true JPWO2021169845A5 (https=) 2024-02-29
JP7807815B2 JP7807815B2 (ja) 2026-01-28

Family

ID=77317937

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022550720A Active JP7807815B2 (ja) 2020-02-24 2021-02-19 ニューレグリンの使用による心不全を予防、治療、又は遅延させるための方法及び組成物
JP2025205790A Pending JP2026062640A (ja) 2020-02-24 2025-11-27 ニューレグリンの使用による心不全を予防、治療、又は遅延させるための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025205790A Pending JP2026062640A (ja) 2020-02-24 2025-11-27 ニューレグリンの使用による心不全を予防、治療、又は遅延させるための方法及び組成物

Country Status (8)

Country Link
US (1) US20230083149A1 (https=)
EP (1) EP4115899A4 (https=)
JP (2) JP7807815B2 (https=)
KR (1) KR20220145870A (https=)
CN (2) CN113289002A (https=)
AU (1) AU2021225283A1 (https=)
CA (1) CA3172439A1 (https=)
WO (1) WO2021169845A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117797243A (zh) * 2022-09-30 2024-04-02 上海泽生科技开发股份有限公司 神经调节蛋白及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE463851B (sv) 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
DE4221256C2 (de) 1992-06-26 1997-07-10 Lancaster Group Ag Galenische Zusammensetzung für die topische Anwendung
US5741511A (en) 1995-04-12 1998-04-21 Sam Yang Co., Ltd. Transdermal drug delivery device for treating erectile dysfunction
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
JP2000502682A (ja) 1995-12-22 2000-03-07 ローカルメッド インコーポレイテッド 血管新生を促進する成長因子の局所的血管内デリバリー
SE9703226D0 (sv) 1997-09-08 1997-09-08 Astra Ab New pharmaceutical composition
JP2001519400A (ja) 1997-10-14 2001-10-23 ケンブリッジ ニューロサイエンス インク． ニューレグリン使用を含む治療法
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
CN104436167A (zh) * 2010-06-12 2015-03-25 上海泽生科技开发有限公司 神经调节蛋白用于治疗心力衰竭的有效剂量
WO2013053076A1 (en) * 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
EP2964249A1 (en) * 2013-03-06 2016-01-13 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
CN105561298A (zh) * 2014-10-17 2016-05-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
CN110835368A (zh) * 2018-08-15 2020-02-25 上海泽生科技开发股份有限公司 神经调节蛋白多肽片段及其用途

Similar Documents

Publication Publication Date Title
Rajpal et al. Factors leading to high morbidity and mortality of COVID‐19 in patients with type 2 diabetes
Saruta et al. Expression and localization of chromogranin A gene and protein in human submandibular gland
Silva et al. The carboxyl-terminal region of the Na+/H+ exchanger interacts with mammalian heat shock protein
JP2004532817A5 (https=)
JP2021513077A5 (https=)
FI120308B (fi) Peptidi, joka pystyy neutraloimaan tai muuntamaan myeliinin emäksisen proteiinin vasta-aineen tuoton
Chanez et al. Platelet‐derived growth factor in asthma
CN115976196B (zh) ErbB3作为肺动脉高压生物标志物和治疗靶点的应用
Ren et al. Transcranial direct current stimulation promotes angiogenesis and improves neurological function via the OXA-TF-AKT/ERK signaling pathway in traumatic brain injury
Li et al. LONP1 facilitates pulmonary artery smooth muscle cell glycolytic reprogramming by degrading MPC1 in pulmonary hypertension
Abounader et al. Associations between neuropeptide Y nerve terminals and intraparenchymal microvessels in rat and human cerebral cortex
JPH02479A (ja) ｓｎＲＮＰ−Ａ抗原及びそのフラグメント
JPWO2021169845A5 (https=)
CN101696234A (zh) 抗类风湿性关节炎的多肽及其在制药中的应用
CN115515620A (zh) 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物
KR20240041833A (ko) 섬유화 질환의 예방 또는 치료용 신규 항체
US5367063A (en) Human phospholipase activating protein and methods for diagnosis of rheumatoid arthritis
Sun et al. Regulation of osteoclast differentiation and inflammatory signaling by TCF8 in periodontitis
Sivitz et al. Time-dependent regulation of rat adipose tissue glucose transporter (GLUT4) mRNA and protein by insulin in streptozocin-diabetic and normal rats
KR102052882B1 (ko) 브로디 신드롬 또는 브로디 병의 예방 또는 치료를 위한 stim2 저해제의 용도
JPWO2019154900A5 (https=)
EP4334724A1 (en) Mature adrenomedullin for therapy stratification of corticosteroids in critically ill patients
RU2198893C2 (ru) Пептидные фрагменты основного белка миелина, фармацевтические композиции на их основе и применение данных композиций для лечения рассеянного склероза
Yang et al. Electroacupuncture Improves Cardiac Function in Mice with Myocardial Infarction through Glu Neurons in Ventrolateral Periaqueductal Gray
Soszynski et al. Endogenous natriuretic factors: atrial natriuretic hormone and digitalis-like substance in Cushing's syndrome